Primary signet ring cell carcinoma of the pancreatic head: A case report

Pancreatic SRCC is a rare, aggressive tumor. Given limited evidence and the risk of side effects, physicians may elect to withhold chemotherapy in select patients, with the exception of neoadjuvant chemotherapy use to facilitate resectability.

Detalles Bibliográficos
Autores principales: Alexander, Dheeraj, Rashid, Lewis, Hollis, Michael, Kavuturu, Srinivas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6878076/
https://www.ncbi.nlm.nih.gov/pubmed/31788286
http://dx.doi.org/10.1002/ccr3.2475
Descripción
Sumario:Pancreatic SRCC is a rare, aggressive tumor. Given limited evidence and the risk of side effects, physicians may elect to withhold chemotherapy in select patients, with the exception of neoadjuvant chemotherapy use to facilitate resectability.

Ejemplares similares